Older adults with prior SARS-CoV-2 infection benefit from two doses of Pfizer/BioNTech vaccine

By | August 2, 2021
The study by researchers from the Ministry of Health, Madrid, Spain, published in the Center of Disease Control and Prevention’s journal Emerging Infectious Diseases, suggests that long-term care facility residents with prior SARS-CoV-2 infection benefit from full vaccination with the Pfizer/BioNTech (BNT162b2) vaccine.